Patients, N | 30 |
Gender, female, n (%) | 27 (90%) |
Age at evaluation, mean (SD), years | 59.8 years (SD 13.2 years) |
Disease duration, mean (SD), years | 13.3 years (SD 15.2 years) |
Fulfilment of ACR-EULAR classification criteria for pSS, n/N (%) | 23/30 (76.6%) |
Parotid gland enlargement, n/N (%) | 22/30 (73.3%) |
Chronic (≥12 months) | 11/22 |
Parotid enlargement of long duration (2–11 months) | 8/22 |
Parotid enlargement of short duration (<2 months) | 3/22 |
Submandibular gland enlargement, n/N (%) | 8/30 (26.7%) |
Chronic (≥12 months) | 5/8 |
Submandibular enlargement of long duration (2–11 months) | 3/8 |
Submandibular enlargement of short duration (<2 months) | 0 |
Duration of parotid and/or submandibular swelling at the time of biopsy, median (25–75 quartiles), months | 12 (4.25–14.75) |
Anti-Ro/SSA or anti-La/SSB positive, n/N (%) | 24/30 (80%) |
Lymphadenopathy, n/N (%) | 11/30 (36.67%) |
Cryoglobulinemia, n/N (%) | 5/30 (16.67%) |
Cryoglobulinaemic vasculitis, n/N (%) | 4/30 (13.3%) |
Serum monoclonal component, n/N (%) | 12/30 (40%) |
Rheumatoid factor positive, n/N (%) | 22/30 (73.3%) |
Leucopenia (WBC<4.0x109/L, n/N (%) | 10/30 (33.3%) |
Low C4, n/N (%) | 13/30 (43,3%) |
ACR, American College of Rheumatology; pSS, primary Sjögren Syndrome; WBC, white blood cells.